Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial

Waked I, Shiha G, Qadish RB. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol. 2016;1(1):36-44.

Publication Type:

Journal Article

Authors:

Waked, I.; Shiha, G.; Qadish, R.B.

Source:

Lancet Gastroenterol Hepatol, Volume 1, Issue 1, p.36-44 (2016)

Cited On:

Export Citation:
RIS Format
Top